AzTrials
AzTrials

Gastric VaricesNCT02693951

Efficiency and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices

A study testing Cefotiam in people with Gastric Varices and Cirrhosis, run by Shanghai Zhongshan Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of the study is to assess the efficiency and safety of prophylactic use of antibiotics in endoscopic injection of tissue adhesive in gastric varices. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Gastric Varices, Cirrhosis
What is being tested?
Cefotiam
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteChina
Study dates
Feb 2016to Sep 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Capable of understanding the purpose and risks of the study and informed consent to participate in the study;
  • age between 18-75 years old;
  • Diagnosis of esophageal gastric varices by gastroscopy
  • Preparation of endoscopic injection of tissue adhesive

Who cannot join

  • No esophageal gastric varices bleeding history;
  • Esophageal varices or gastric varices which temporarily won't be treated by endoscopic therapy;
  • The cefotiam contraindications: such as allergies, pregnancy etc;
  • Patients with the other malignant tumor except liver cancer;
  • The preoperative diagnosis of infection;
  • The large amount of ascites;
  • The acute bleeding period (< 5 days);
  • Patients refused to participate in the study.

Trial locations and contacts

1 site in 1 country.

Shiyao Chen, Professor contact

86-13601767310

chen.shiyao@zs-hospital.sh.cn

China1 site, 1 recruiting
  • Shanghai Zhongshan Hospital

    Shanghai, Shanghai Municipality, 200032

    Chengfeng Liu, Doctor, 86-15201927474, 09301010167@fudan.edu.cn

    Shiyao Chen, MD

    Recruiting

Other trials in China

About this study

Official title: Efficiency and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices: A Randomized Controlled Trial

The purpose of the study is to assess the efficiency and safety of prophylactic use of antibiotics in endoscopic injection of tissue adhesive in gastric varices.

Read the detailed description

At present, there is still a controversy about the application of antibiotics in the treatment of patients with non acute hemorrhage of esophageal varices. This study is a randomized controlled trial. Patients randomly enter two treatment groups:

  1. the prophylactic use of antibiotics group and
  2. the non-prophylactic use of antibiotics group

Treatment allocation is by block randomization with an equal number for both groups. The incidence of infection after endoscopic treatment will be analyzed.

Being tested
Cefotiam
Keywords
gastric varices, endoscopic injection of tissue adhesive
Medical subject headings
Esophageal and Gastric Varices, Fibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CefotiamDrug

    Also called HaiTiShu

    Prophylactic use of antibiotics group: Half an hour before endoscopic treatment, cefotiam 2.0g intravenous

Study groups in NCT02693951
Study groupRoleWhat they receive
the prophylactic use of antibiotics groupExperimentalHalf an hour before endoscopic treatment, cefotiam 2.0g intravenous
Receives: Drug: Cefotiam
ControlNo interventionRoutine endoscopic examination and treatment. Antibiotics are not used before endoscopic treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The incidence of infection after endoscopic treatment

    Patients will receive body temperature, blood routine, inflammatory markers examination before and after endoscopic treatment.

    Measured: 1 week

Secondary outcomes (2)
  1. Rebleeding rate

    Patients will receive an endoscopic examination after patients have been followed up for 2 months.

    Measured: 2 months

  2. Mortality rate

    The investigators observe the mortality events during 2 months

    Measured: 2 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Feb 2016 (estimated)
  2. Study startFeb 2016
  3. Primary completionJan 2017 (estimated)
  4. Study completionSep 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02693951
Sponsor's protocol ID
CSY-LCF-2016
Status last verified
Jan 2017
First submitted
18 Feb 2016
Last updated
6 Jan 2017
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Cefotiam in people with Gastric Varices and Cirrhosis, run by Shanghai Zhongshan Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Jan 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Shiyao Chen, Professor (86-13601767310, chen.shiyao@zs-hospital.sh.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The incidence of infection after endoscopic treatment (time frame: 1 week). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in